sorafenib has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 16 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one) | Trials (2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one) | Recent Studies (post-2010) (2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 4,823 | 5 | 1,810 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW | 1 |
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Hah, JM; Kim, H; Kim, M; Kim, MH; Sim, T; Yoo, KH; Yu, H | 1 |
| Hah, JM; Kim, H; Kim, M; Lee, J; Yu, H | 1 |
| Aman, W; Hah, JM; Im, D; Jung, K; Yang, S | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW | 1 |
| Cohen, L; Gao, Y; Gu, K; Li, HX; Meng, ZQ; Wang, P; Xu, LT; Xu, LY; Yang, PY | 1 |
| Doudican, NA; Orlow, SJ; Quay, E; Zhang, S | 1 |
| Corey, SJ; Park, BJ; Whichard, ZL | 1 |
| Dekervel, J; Nevens, F; Van Cutsem, E; van Malenstein, H; van Pelt, J; Verslype, C; Windmolders, P | 1 |
| Cai, JB; Dong, ZR; Fan, J; Gao, DM; Gao, PT; Hu, ZQ; Huang, XY; Ke, AW; Li, KS; Shen, YH; Shi, GM; Tian, MX; Zhang, C; Zhang, PF | 1 |
| A, M; A, Z; E, L; I, W; J, JG; J, SW; W, R | 1 |
2 review(s) available for sorafenib and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
14 other study(ies) available for sorafenib and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin | 2007 |
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
Topics: Amides; Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Computer Simulation; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; raf Kinases; Sorafenib; Structure-Activity Relationship | 2011 |
Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
Topics: Amides; Azepines; Cell Growth Processes; Cell Line, Tumor; Humans; Melanoma; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Pyrazoles; Structure-Activity Relationship; U937 Cells | 2011 |
Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Isoxazoles; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Structure-Activity Relationship; U937 Cells | 2015 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Topics: Androstadienes; Apoptosis; Benzenesulfonates; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Flavonoids; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mitogen-Activated Protein Kinase Kinases; Morpholines; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sirolimus; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Wortmannin | 2008 |
Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Bufanolides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Gene Expression Regulation, Enzymologic; Humans; Liver Neoplasms; Microscopy, Electron, Transmission; Morpholines; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways.
Topics: Anthracenes; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Melanoma; Morpholines; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2011 |
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Epothilones; Female; Humans; Morpholines; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Pyrimidines; Signal Transduction; Sirolimus; Sorafenib; Tamoxifen; Thiazoles | 2012 |
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
Topics: Anilides; Antineoplastic Agents; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Keratin-19; Liver Neoplasms; Morpholines; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; Vimentin | 2013 |
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Focal Adhesion Kinase 1; Galectin 1; Humans; Integrin alphaVbeta3; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Morpholines; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Sorafenib; Survival Rate | 2016 |
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chromones; Glioma; Humans; Morpholines; Sorafenib; Survival Analysis; Transfection | 2021 |